EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)

PURPOSE BIM activation is essential for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)–triggered apoptosis in EGFR-mutant non–small-cell lung cancer (NSCLC). A deletion in the intron two of the BIM gene results in generation of alternatively spliced isoforms that impairs their apoptotic response to TKIs, conferring the NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions (BIMdel). MATERIALS AND METHODS A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction analysis and direct sequencing of DNA. BIM protein expression was investigated by immunohistochemistry, and BIM mRNA levels by reverse transcriptase-polymerase chain reaction. Clinical characteristics, overall survival, progression-free survival (PFS), overall response rate (ORR), and treatment-related adverse events were compared between both groups. RESULTS Thirty-three patients were included; 15 received EGFR-TKIs, and 18 received EGFR-TKIs plus Bev. The median age was 63 years, with a majority of recruited female patients. All included individuals had an Eastern Cooperative Oncology Group performance score of 2 or less. The addition of Bev resulted in a significantly higher ORR (94.4% v 40%, P > .001). Median PFS was longer with the use of the combination therapy (11.12 v 7.87 months; P = .001). Median overall survival tended to be longer in the EGFR-TKIs plus Bev (30.9 v 25.4 months; P = .06) but failed to reach statistical significance. Response in terms of both partial and complete as well as overall favorably affected PFS. CONCLUSION EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.

[1]  Jie Wu,et al.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer , 2019, Signal Transduction and Targeted Therapy.

[2]  D. Muntham,et al.  Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC , 2019, Asian Pacific journal of cancer prevention : APJCP.

[3]  J. Field,et al.  Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review , 2019, BMC Cancer.

[4]  Fengbin Wang,et al.  BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer , 2019, Medicine.

[5]  C. Powell,et al.  Global Epidemiology of Lung Cancer , 2019, Annals of global health.

[6]  S. Ota,et al.  Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy , 2019, Case Reports in Oncology.

[7]  A. Cardona,et al.  Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century. , 2018, Journal of thoracic disease.

[8]  Y. Nishimura,et al.  Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy , 2018, Cells.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  Li-xin Wu,et al.  Association between BIM polymorphism and lung cancer outcomes: a meta-analysis. , 2018, Cellular and molecular biology.

[11]  F. Hirsch,et al.  EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. , 2018, Lung cancer.

[12]  K. Tam,et al.  Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes , 2018, International journal of biological sciences.

[13]  Yong He,et al.  Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction , 2017, Oncotarget.

[14]  B. Han,et al.  Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer , 2017, Oncotarget.

[15]  Huqin Zhang,et al.  Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies , 2017, Oncotarget.

[16]  Seung-Woo Hong,et al.  Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway. , 2017, Lung cancer.

[17]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[18]  S. Franco,et al.  BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations , 2016, Oncotarget.

[19]  J. Shih,et al.  Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma. , 2016, JAMA oncology.

[20]  V. Adamo,et al.  A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives , 2015, Oncotarget.

[21]  J. Ahn,et al.  The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  E. Esteban,et al.  Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. , 2015, Cancer epidemiology.

[23]  F. Hirsch,et al.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer , 2014, Cancer.

[24]  Yi-Song Wang,et al.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer , 2014, Journal of Molecular Medicine.

[25]  E. Felip,et al.  The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial , 2014, Clinical Cancer Research.

[26]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[28]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[29]  C. Sorenson,et al.  Opposing effects of bim and bcl-2 on lung endothelial cell migration. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[30]  Balazs Halmos,et al.  EGFR-mutated lung cancer: a paradigm of molecular oncology , 2010, Oncotarget.

[31]  P. Choong,et al.  Bim-targeted cancer therapy: A link between drug action and underlying molecular changes , 2009, Molecular Cancer Therapeutics.

[32]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[33]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[34]  Masato Nakamura,et al.  Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. , 2005, Oncology reports.

[35]  M. Ando,et al.  Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. , 2017, The journal of medical investigation : JMI.

[36]  Supplementary Figures and Tables , 2022 .